Endothelial cells, which line blood vessels, continuously interact with blood cells, but the latter do not adhere under usual circumstances. This is crucial since inappropriate activation of leukocytes and platelets would lead to vascular damage and thrombosis. We have studied the endothelial cell synthesis of lipid mediators that influence these interactions. One interest has been the regulation of synthesis of platelet-activating factor, a potent phospholipid autacoid with diverse functions, including mediation of the adhesion of leukocytes to activated endothelial cells. It also increases vascular permeability and stimulates smooth muscle cell growth. We found that its synthesis is tightly regulated, and described mechanisms at the initiating and subsequent steps. In preliminary studies we have substantially purified the enzyme responsible for the second step in the synthesis of PAF, the acetyltransferase, which we showed to be important in determining the amount of PAF synthesized by endothelial cells. We have established methods for examining the transfer of PAF to the cell surface and its expression on the cell surface. Another key lipid mediator is prostacyclin (PGI2), a metabolite of arachidonic acid, which is a potent vasodilator and prevents platelet aggregation. One component of the regulation of PGI2 synthesis is the availability of arachidonate, which requires its release from phospholipids. We found that the release of arachidonate is augmented in proliferating cells compared to confluent cells and described the mechanism for this change. The amount of PGI2 synthesized by endothelial cells is increased after exposure to cytokines such as TNF and IL- 1, and we found that both increased release of arachidonate and increased expression of cyclooxygenase (prostaglandin H synthase; PGHS) occur. We have isolated a cDNA encoding a novel form of the PGHS (Type II). We propose to complete the purification of acetyl coA:lysoPAF acetyltransferase, prepare antibodies to it and isolate a cDNA. We will use these reagents to examine the regulation of the acetyltransferase, which probably undergoes phosphorylation/dephosphorylation, and also may be regulated by increased synthesis. We will test the hypothesis that PAF can serve as an intracellular messenger. We will determine the mechanism(s) by which PAF is transferred from its site of synthesis an internal membrane to the surface of the endothelial cell. Additionally, we will characterize binding sites for PAF on the surface of endothelial cells that do not appear to be the known PAF receptor. We will determine the mechanism by which increased release of arachidonate occurs in cells exposed to cytokines, and will define the basis for increased expression of PGHS (both types). Finally, we will determine whether the increased expression of this enzyme can be regulated pharmacologically. These experiments will have important clinical implications since prostaglandin synthesis is the target for most anti-inflammatory, and some anti-thrombotic, agents.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL034127-10
Application #
2217456
Study Section
Medical Biochemistry Study Section (MEDB)
Project Start
1985-04-01
Project End
1998-03-31
Budget Start
1994-04-01
Budget End
1995-03-31
Support Year
10
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Topham, M K; Carveth, H J; McIntyre, T M et al. (1998) Human endothelial cells regulate polymorphonuclear leukocyte degranulation. FASEB J 12:733-46
Spirio, L N; Dixon, D A; Robertson, J et al. (1998) The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli. Cancer Res 58:4909-12
Bunting, M; Lorant, D E; Bryant, A E et al. (1997) Alpha toxin from Clostridium perfringens induces proinflammatory changes in endothelial cells. J Clin Invest 100:565-74
Kutchera, W; Jones, D A; Matsunami, N et al. (1996) Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A 93:4816-20
Elstad, M R; Parker, C J; Cowley, F S et al. (1994) CD11b/CD18 integrin and a beta-glucan receptor act in concert to induce the synthesis of platelet-activating factor by monocytes. J Immunol 152:220-30
Whatley, R E; Satoh, K; Zimmerman, G A et al. (1994) Proliferation-dependent changes in release of arachidonic acid from endothelial cells. J Clin Invest 94:1889-900
Venable, M E; Zimmerman, G A; McIntyre, T M et al. (1993) Platelet-activating factor: a phospholipid autacoid with diverse actions. J Lipid Res 34:691-702
Fujimoto, T; Stroud, E; Whatley, R E et al. (1993) P-selectin is acylated with palmitic acid and stearic acid at cysteine 766 through a thioester linkage. J Biol Chem 268:11394-400
Whatley, R E; Stroud, E D; Bunting, M et al. (1993) Growth-dependent changes in arachidonic acid release from endothelial cells are mediated by protein kinase C and changes in diacylglycerol. J Biol Chem 268:16130-8
Zimmerman, G A; Lorant, D E; McIntyre, T M et al. (1993) Juxtacrine intercellular signaling: another way to do it. Am J Respir Cell Mol Biol 9:573-7

Showing the most recent 10 out of 44 publications